Last reviewed · How we verify
NCT04904952
Effect of N-acetylcysteine as Add on Therapy With SSRI in Moderate to Severe OCD Patients
NA trial testing N-acetylcysteine tablet 600mg in OCD in 60 participants. Status unknown.
10 January 2022
Quick facts
| Lead sponsor | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 13 March 2020 |
| Primary completion | 10 January 2022 |
| Estimated completion | 10 January 2022 |
| Sites | 2 locations across Bangladesh |
Drugs / interventions tested
- N-acetylcysteine tablet 600mg — full drug profile →
- Placebo tablet 600mg — full drug profile →
Conditions studied
- OCD — all drugs for OCD →
Sponsor
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Who can join
Adults 18 to 60, any sex, with OCD. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Title: Effect of n-acetylcysteine as add-on therapy with Selective Serotonin Reuptake Inhibitors in moderate to severe Obsessive Compulsive Disorder patients. Purpose of the study: To assess the effects of the addition of n-acetylcysteine with SSRIs on the severity of symptoms in obsessive-compulsive disorder patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04904952
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for OCD
Currently open trials in the same condition.
- NCT06934525 — Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings · NA · recruiting
- NCT06282146 — Testing a Transdiagnostic TMS Treatment Target · EARLY_PHASE1 · active not recruiting
- NCT05994053 — Neuromodulation for a Novel OCD Biomarker and Treatment · NA · recruiting
- NCT06978452 — Behavioural Development, Long-term Outcomes and Opportunities to Optimize Youth Mental Health Trajectories · recruiting
- NCT06731426 — Multi-session, Personalized Cognitive Bias Modification for Thought-Action-Fusion · NA · recruiting
Other Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh trials
Trials by the same sponsor.
- NCT07507045 — Education-Based Oral Health Promotion Intervention During Pregnancy: Implementation Protocol in Bangladesh · NA · not yet recruiting
- NCT07537634 — Vonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication · Phase 4 · not yet recruiting
- NCT07161336 — Role of Methotrexate in Ultrasound Proven Synovitis in Primary Knee OA · Phase 2 · recruiting
- NCT06960694 — Effect of L-carnitine on Disease Activity in Patients With Mild to Moderate Knee Osteoarthritis · Phase 2 · completed
- NCT07123922 — Effect of Silymarin as Add on Therapy on Oxidative Stress, Pulmonary Function and Quality of Life in Stable COPD Patient · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04904952 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- Last refreshed: 16 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04904952.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing